Literature DB >> 27514452

Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.

Swati Agarwal1, Anuradha Yadav1, Rajnish Kumar Chaturvedi2.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors and they serve to be a promising therapeutic target for several neurodegenerative disorders, which includes Parkinson disease, Alzheimer's disease, Huntington disease and Amyotrophic Lateral Sclerosis. PPARs play an important role in the downregulation of mitochondrial dysfunction, proteasomal dysfunction, oxidative stress, and neuroinflammation, which are the major causes of the pathogenesis of neurodegenerative disorders. In this review, we discuss about the role of PPARs as therapeutic targets in neurodegenerative disorders. Several experimental approaches suggest potential application of PPAR agonist as well as antagonist in the treatment of neurodegenerative disorders. Several epidemiological studies found that the regular usage of PPAR activating non-steroidal anti-inflammatory drugs is effective in decreasing the progression of neurodegenerative diseases including PD and AD. We also reviewed the neuroprotective effects of PPAR agonists and associated mechanism of action in several neurodegenerative disorders both in vitro as well as in vivo animal models.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mitochondrial biogenesis; Mitochondrial dynamics; Mitochondrial dysfunction; Neurodegenerative disorder; PGC-1 alpha; Pioglitazone; Rosiglitazone

Mesh:

Substances:

Year:  2016        PMID: 27514452     DOI: 10.1016/j.bbrc.2016.08.043

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  50 in total

1.  Iso-α-acids, Bitter Components of Beer, Prevent Inflammation and Cognitive Decline Induced in a Mouse Model of Alzheimer's Disease.

Authors:  Yasuhisa Ano; Atsushi Dohata; Yoshimasa Taniguchi; Ayaka Hoshi; Kazuyuki Uchida; Akihiko Takashima; Hiroyuki Nakayama
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

2.  TSPO Modulates IL-4-Induced Microglia/Macrophage M2 Polarization via PPAR-γ Pathway.

Authors:  Dandan Zhou; Lei Ji; Youguo Chen
Journal:  J Mol Neurosci       Date:  2019-12-26       Impact factor: 3.444

Review 3.  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors:  Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal:  Nat Rev Drug Discov       Date:  2018-09-28       Impact factor: 84.694

4.  [Activation of PPARγ pathway enhances cellular anti-oxidant capacity to protect long-term cultured primary rat neural cells from apoptosis].

Authors:  Huqing Wang; Jiaxin Fan; Wanying Chen; Zhen Gao; Guilian Zhang; Haiqin Wu; Xiaorui Yu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-01-30

Review 5.  Role of PGC-1α in Mitochondrial Quality Control in Neurodegenerative Diseases.

Authors:  Qi Zhang; Yu-Hong Lei; Jue-Pu Zhou; Ye-Ye Hou; Zheng Wan; Hong-Lei Wang; Hao Meng
Journal:  Neurochem Res       Date:  2019-08-13       Impact factor: 3.996

6.  Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone.

Authors:  Timothy A Simeone; Stephanie A Matthews; Kristina A Simeone
Journal:  Epilepsia       Date:  2017-05-28       Impact factor: 5.864

7.  Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice.

Authors:  Lu Song; Hao Wang; Ying-Jie Wang; Jin-Liang Wang; Qing Zhu; Feng Wu; Wei Zhang; Bo Jiang
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

9.  Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.

Authors:  Xavier Nadal; Carmen Del Río; Salvatore Casano; Belén Palomares; Carlos Ferreiro-Vera; Carmen Navarrete; Carolina Sánchez-Carnerero; Irene Cantarero; Maria Luz Bellido; Stefan Meyer; Gaetano Morello; Giovanni Appendino; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2017-11-02       Impact factor: 8.739

Review 10.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.